Skip to main content
Clinical Trials/ChiCTR2100044589
ChiCTR2100044589Active, not recruitingNot Applicable

白内障摘除联合散光人工晶状体植入多中心临床应用及规范化管理

上海市申康发展中心4 sites in 1 country120 target enrollmentStarted: April 1, 2021Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
120
Locations
4
Primary Endpoint
残留散光

Study Overview

Brief Summary

通过白内障超声乳化吸除联合散光晶体植入术提高裸眼视力,减少残余散光,有效提升脱镜率;并对该术式进行规范化管理,建立相应的质控体系。

Study Design

Study Type
观察性研究
Primary Purpose
连续入组
Masking
N/a

Eligibility Criteria

Ages
18 to 80 (—)
Sex
All

Inclusion Criteria

  • ① 50-80 岁待行白内障摘除联合人工晶体植入术,性别不限;
  • ② 经 IOL master 或角膜地形图测得散光数值大于 1.0D,小于 4.0D;
  • ③ 角膜地形图观察散光形态为规则性散光。

Exclusion Criteria

  • ① 角膜变性、角膜营养不良等影响视轴区观察的角膜疾病;
  • ② 曾患葡萄膜炎等影响瞳孔散大疾病;
  • ③ 瞳孔无法散大至 6mm 以上者;
  • ④ 既往青光眼或瞳孔疾病影响瞳孔括约肌功能疾病。

Arms & Interventions

Case series

超声乳化吸除联合散光晶体植入术

Outcomes

Primary Outcomes

残留散光

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
上海市申康发展中心

Study Sites (4)

Loading locations...

Similar Trials